Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Grand Pharma Acquires Rights to Mitral Valve Replacement Device

publication date: Jan 27, 2022

Hong Kong's Grand Pharmaceutical acquired greater China rights to the Saturn Transcatheter Mitral Valve Replacement (TMVR) system developed by Milan's InnovHeart. Grand Pharma will make an equity investment in InnovHeart, plus pay upfront licensing fees, milestone payments and structured royalties. InnovHeart said the transaction, including other investors' participation in the Series C financing, would total up to $55 million. Grand Pharma led the Series C equity round. It was joined by existing investors Genextra, Panakes Partners and Indaco Venture Partners. More details....

Stock Symbol: (HK: 00512)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China